CVM
CEL-SCI Corp
AMEX: CVM · HEALTHCARE · BIOTECHNOLOGY
$1.19
-10.46% today
Updated 2026-06-05
Market cap
$19.40M
P/E ratio
—
P/S ratio
92.88x
EPS (TTM)
$-2.15
Dividend yield
—
52W range
$1 – $13
Volume
0.6M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D3.0
Quality
D3.0
Profitability
D5.3
Valuation
C+3/9
Piotroski F-Score
Weak
-28.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →205 stocks currently score above 75
Price targets
Analyst target
$25.00
+2000.84%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -28.66 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.02M
- Revenue declining -62.70% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $28560.00 |
| Net income | $-38.27M | $-32.37M | $-26.92M | $-25.41M | $-5.47M |
| EPS | — | — | — | — | $-2.15 |
| Free cash flow | $-18.90M | $-23.22M | $-18.91M | $-17.16B | $-4.02M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
CEL-SCI Corp trades at $1.19. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -28.66, it sits in the distress. TTM revenue stands at $28560.00.
Frequently asked questions
What is CEL-SCI Corp's stock price?
CEL-SCI Corp (CVM) trades at $1.19, on a P/S of 92.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is CEL-SCI Corp overvalued?
CEL-SCI Corp carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of CEL-SCI Corp (CVM)?
The 12-month analyst consensus target is $25.00, about 2000.8% above the current $1.19. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is CEL-SCI Corp's revenue?
CEL-SCI Corp's trailing twelve-month revenue is $28560.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
CEL-SCI Corp's Altman Z-Score is -28.66, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio92.88x
ROE-330.21%
Beta0.60
50D MA$1.86
200D MA$5.13
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—